GSK sells liver disease drug candidate to Alfasigma for $690m
Posted:
Italy-based Alfasigma will acquire worldwide development, manufacturing, and commercialisation duties for linerixibat, GSK’s ileal bile acid transporter (IBAT) inhibitor being developed for cholestatic pruritus in primary biliary cholangitis (PBC).
The Bacillus Calmette-Guérin (BCG) vaccine prevents severe forms of tuberculosis (TB) and is the world’s most widely used vaccine, as well as the oldest vaccine still in use.
Read more here.
Cigna's Evernorth is investing $100 million through 2028 in specialty pharmacy care.
The AI program called Pharmacy Forward is expected to generate approximately $400 million in value by the end of 2028, according to Evernorth.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us